Mice, myeloid cells, and dengue: a new model for unraveling vascular leakage mysteries

Front Microbiol. 2024 Mar 14:15:1367672. doi: 10.3389/fmicb.2024.1367672. eCollection 2024.

Abstract

Introduction: Severe dengue is thought to be caused by an excessive host immune response.

Methods: To study the pathogenesis of severe dengue, we developed a novel model using LysM Cre+Ifnarflox/flox mice carrying depleted Ifnar expression only in subsets of murine myeloid cells.

Results: Although dengue virus (DENV) clinical isolates were not virulent in LysM Cre+Ifnarflox/flox mice, mouse-adapted DV1-5P7Sp and DV3P12/08P4Bm, which were obtained by passaging the spleen or bone marrow of mice, demonstrated 100% lethality with severe vascular leakage in the liver and small intestine. DV1-5P7Sp and DV3P12/08P4Bm harbored five and seven amino acid substitutions, respectively. Infection also induced neutrophil infiltration in the small intestine, and increased expression of IL-6 and MMP-8 and blockade of TNF-α signaling protected the mice, as demonstrated in a previous severe dengue mouse model using C57/BL6 mice lacking both IFN-α/β and IFN-γ receptors. Notably, the new models with DV1-5P7Sp and DV3P12/08P4Bm showed an increased proliferative capacity of the adapted viruses in the thymus and bone marrow.

Discussion: These observations suggest that myeloid cell infection is sufficient to trigger cytokine storm-induced vascular leakage. This model can refine the factors involved in the pathology of severe dengue leading to vascular leakage.

Keywords: bone marrow suppression; cytokine storm; myeloid cells; pathogenic mechanisms; severe dengue; vascular leakage; viral adaptation.

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by a grant-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan (15K148885, 17K08145, and 21K05981) and by the Japan Agency for Medical Research and Development (AMED) (19fk0108080j0201).